K-ras is the most commonly mutated oncogene in pancreatic cancer and its activation in murine models is sufficient to recapitulate the spectrum of lesions seen in human pancreatic ductal adenocarcinoma (PDAC). Recent studies suggest that Notch receptor signaling becomes reactivated in a subset of PDACs, leading to the hypothesis that Notch1 functions as an oncogene in this setting. To determine whether Notch1 is required for K-ras-induced tumorigenesis, we used a mouse model in which an oncogenic allele of K-ras is activated and Notch1 is deleted simultaneously in the pancreas. Unexpectedly, the loss of Notch1 in this model resulted in increased tumor incidence and progression, implying that Notch1 can function as a tumor suppressor gene in...
Background: Recent studies have implicated aberrant Notch signaling in breast cancers. Yet, relati...
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related dea...
The majority of human pancreatic cancers have activating mutations in the KRAS proto-oncogene. These...
K-ras is the most commonly mutated oncogene in pancreatic cancer and its activation in murine models...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers, with a five-yea...
<div><p>Pancreatic ductal adenocarcinoma is believed to arise from precursor lesions termed pancreat...
Pancreatic ductal adenocarcinoma is believed to arise from precursor lesions termed pancreatic intra...
Pancreatic cancer is one of the most fatal malignancies lacking effective therapies. Notch signaling...
Pancreatic cancer is one of the most fatal malignancies lacking effective therapies. Notch signaling...
PURPOSE: Aberrant activation of the Notch signaling pathway is commonly observed in human pancreatic...
Background: Pancreatic cancer stem cells (CSCs) represent a small subpopulation of pancreatic cancer...
Pancreatic cancer stem cells (CSCs) represent a small subpopulation of pancreatic cancer cells that ...
Pancreatic ductal adenocarcinoma (PDAC) is the 5th commonest cause of cancer related deaths in the U...
Truncated Notch receptors have transforming activity in vitro and in vivo. However, the role of wild...
Introduction: Pancreatic cancer is a malignancy with a very poor prognosis, and therefore insights i...
Background: Recent studies have implicated aberrant Notch signaling in breast cancers. Yet, relati...
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related dea...
The majority of human pancreatic cancers have activating mutations in the KRAS proto-oncogene. These...
K-ras is the most commonly mutated oncogene in pancreatic cancer and its activation in murine models...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers, with a five-yea...
<div><p>Pancreatic ductal adenocarcinoma is believed to arise from precursor lesions termed pancreat...
Pancreatic ductal adenocarcinoma is believed to arise from precursor lesions termed pancreatic intra...
Pancreatic cancer is one of the most fatal malignancies lacking effective therapies. Notch signaling...
Pancreatic cancer is one of the most fatal malignancies lacking effective therapies. Notch signaling...
PURPOSE: Aberrant activation of the Notch signaling pathway is commonly observed in human pancreatic...
Background: Pancreatic cancer stem cells (CSCs) represent a small subpopulation of pancreatic cancer...
Pancreatic cancer stem cells (CSCs) represent a small subpopulation of pancreatic cancer cells that ...
Pancreatic ductal adenocarcinoma (PDAC) is the 5th commonest cause of cancer related deaths in the U...
Truncated Notch receptors have transforming activity in vitro and in vivo. However, the role of wild...
Introduction: Pancreatic cancer is a malignancy with a very poor prognosis, and therefore insights i...
Background: Recent studies have implicated aberrant Notch signaling in breast cancers. Yet, relati...
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related dea...
The majority of human pancreatic cancers have activating mutations in the KRAS proto-oncogene. These...